March 19, 2004

News Release: Ceapro Issues Progress Report for AccuScreen(TM) Trials

Ceapro Inc. ('Ceapro') (TSX-VEN: CZO) today presented a report to the Metis Nation Diabetes Conference detailing the progress on the AccuScreen(TM) pre-marketing trials. The studies commenced in January 2004 with the First Nation's Blood Tribe in Standoff, Alberta, located 150 km southeast of Calgary. AccuScreen(TM) dw
identified 20 out of 44 (45%) of test subjects as pre-diabetics with impaired glucose tolerance, whereas the routine diabetes tests identified only 10 subjects as being at risk. This positive result confirmed the effectiveness of AccuScreen(TM) in the early screening to identify those individuals with type 2 diabetes and impaired glucose tolerance. The trials were conducted on an independent basis by staff of the Blood Tribe Department of Health. The trial protocol was designed to evaluate the results of AccuScreen(TM) testing in a random population of subjects.

Dr. Mark Redmond, Ceapro President and CEO stated, 'This is an important positive result for Ceapro and AccuScreen(TM). Although not a study endpoint, this significant data will be useful in finalizing decisions for next steps for AccuScreen(TM) and how to provide the healthcare industry with an important tool in the fight against diabetes.'

Redmond continued, 'Diabetes is a growing global epidemic. The World Health Organization estimates the global number of diabetics will increase from 177 million to 370 million by 2030. However, it is estimated that the number of pre-diabetics is double the number of diabetics. The screening of pre-diabetes is critical in the prevention or delay of onset of diabetes because pre-diabetes is reversible with early intervention. Such intervention demands early detection - a role that AccuScreen(TM) fulfils.'

The marketing trials were announced on November 14, 2003 and are a part of a broader strategy to conduct pre-commercial trials in three distinct market sectors: First Nation's Communities, Industrial and Workplace Health, and Public Health. Work is in now progress in all sectors. Trials are expected to be completed before the end of 2004.

About AccuScreen(TM)

AccuScreen(TM) is a simple, rapid point-of-care screening tool for the identification of elevated blood glucose. Individuals identified as pre- diabetic or diabetic with AccuScreen are recommended to consult their family physician for diagnosis, treatment, education, and support.

About Ceapro

Ceapro is a biotechnology company that develops and commercializes natural products for medical, cosmetic, and animal health industries using proprietary technology and renewable resources.

Ceapro is one of Alberta's 30 Fastest Growing Companies for 2004.

THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing and results of clinical trials, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

CONTACT: Dr. Mark Redmond, President and Chief Executive Officer, Ceapro Inc., Telephone: (780) 917-8382


WEBSITE This email address is being protected from spambots. You need JavaScript enabled to view it.